In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Related Content

Young patients with small-cell lung cancer had less favorable progression-free survival with chemoimmunotherapy.

Chemoimmunotherapy Less Safe, Efficacious in Younger ES-SCLC Population

Tim Cortese

August 17th 2025

Article

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

August 17th 2025

Podcast

Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC

Russ Conroy

August 17th 2025

Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP

August 17th 2025

Podcast

In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese

August 17th 2025

Article

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

November 2015 News Roundup

Newsletter